Remove Drug Delivery Remove In-Vitro Remove Marketing Remove Sales
article thumbnail

Changing Faces: biopharma hires from November 2022

pharmaphorum

Woxström, a 26-year veteran of AstraZeneca, will lead sales, marketing, and commercial operations for 30 European countries plus Canada. Prior to 2022, she did sales and marketing at Pfizer, Allergan, DuPont Pharma, and Johnson & Johnson. Read on for a round-up of some of the biggest moves that crossed our desks.

Sales 52
article thumbnail

XPhyto Announces RT-PCR Test for Point-of-Care COVID-19 Detection

The Pharma Data

European market launch of both COVID-19 tests planned for Q1 2021. The test is planned for commercial launch as a CE-IVD ( in vitro diagnostic) certified product in the European Union in Q1 2021. 25-minute RT-PCR lab test to complement 15-minute rapid test. XPhyto Therapeutics Corp. ON BEHALF OF THE BOARD.

RNA 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Progenity Announces Pricing of Public Offering of Common Stock – Dec 03, 2020

The Pharma Data

The issuance and sale of the notes are scheduled to settle on December 7, 2020, subject to customary closing conditions. Progenity provides in vitro molecular tests designed to improve lives by providing actionable information that helps guide patients and physicians in making medical decisions during key life stages. SAN DIEGO, Dec.

article thumbnail

Progenity, Inc. Prices $75.0 Million Convertible Senior Notes Offering – Dec 03, 2020

The Pharma Data

The issuance and sale of the notes are scheduled to settle on December 7, 2020, subject to customary closing conditions. (NASDAQ: PROG) today announced the pricing of its offering of $75.0 million principal amount of notes. The notes will mature on December 1, 2025, unless earlier repurchased, redeemed or converted.

Sales 40
article thumbnail

What to expect from PEGS Europe 2023: Day 1

Drug Discovery World

Sebastian Jaeger, PhD, Senior Scientist, ADCs & Targeted NBE Therapeutics, Merck Healthcare KGaA, on: ‘Evaluation of Fcab-drug conjugates as a novel antibody-based format for targeted drug delivery’.